论文部分内容阅读
目的探讨利福喷丁治疗肺结核的临床疗效及安全性。方法选新发肺结核病例121例,随机分为两组,其中观察组63例,对照组58例。对照组按照标准化疗方案给予常规抗结核治疗;观察组将利福平替换为利福喷丁,其他标准抗结核药物相同。疗程均为6个月。SAS9.1进行数据统计分析。结果经卡方检验,两组病例痰菌阴转率和空洞闭合率差异均有统计学意义(均P<0.05);经Wilcoxon秩和检验,两组病灶吸收情况差异有统计学意义(P<0.05);经重复测量数据方差分析,不同治疗时间谷丙转氨酶(ALT)、谷草转氨酶(AST)水平组间差异有统计学意义(均P<0.05)。结论利福喷丁联合其他标准抗结核药物治疗肺结核疗效显著,肝毒性小,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of rifapentine in the treatment of pulmonary tuberculosis. Methods 121 cases of newly diagnosed pulmonary tuberculosis were selected and randomly divided into two groups, 63 cases in observation group and 58 cases in control group. The control group received conventional anti-TB treatment according to the standard chemotherapy regimen; the observation group replaced rifampin with rifapentine, and the other standard anti-TB drugs were the same. Course of treatment are 6 months. SAS9.1 for statistical analysis. Results By chi-square test, the difference of sputum negative conversion rate and void closure rate between the two groups were statistically significant (all P <0.05). The Wilcoxon rank sum test showed that there was significant difference in absorption between the two groups (P < 0.05) .Analysis of ANOVA showed that there was significant difference between ALT and AST levels at different treatment time (all P <0.05). Conclusion rifapentine combined with other standard anti-TB drugs for the treatment of pulmonary tuberculosis significant effect, small hepatotoxicity, worthy of clinical application.